1. Kim TW, Choung HK, Khwarg SI, Hwang JM, Yang HJ. Obesity may not be a risk factor for idiopathic intracranial hypertension in Asians. Eur J Neurol. 2008; 15:876–879.
Article
2. Wakerley BR, Mollan SP, Sinclair AJ. Idiopathic intracranial hypertension: update on diagnosis and management. Clin Med (Lond). 2020; 20:384–388.
Article
3. Markey KA, Mollan SP, Jensen RH, Sinclair AJ. Understanding idiopathic intracranial hypertension: mechanisms, management, and future directions. Lancet Neurol. 2016; 15:78–91.
Article
4. Miah L, Strafford H, Fonferko-Shadrach B, Hollinghurst J, Sawhney IM, Hadjikoutis S, et al. Incidence, prevalence and healthcare outcomes in idiopathic intracranial hypertension: a population study. Neurology. 2021; 96:e1251–e1261.
5. Miyachi S, Hiramatsu R, Ohnishi H, Takahashi K, Kuroiwa T. Endovascular treatment of idiopathic intracranial hypertension with stenting of the transverse sinus stenosis. Neurointervention. 2018; 13:138–143.
Article
6. Hoffmann J, Mollan SP, Paemeleire K, Lampl C, Jensen RH, Sinclair AJ. European headache federation guideline on idiopathic intracranial hypertension. J Headache Pain. 2018; 19:93.
Article
7. Fargen KM. Idiopathic intracranial hypertension is not idiopathic: proposal for a new nomenclature and patient classification. J Neurointerv Surg. 2020; 12:110–114.
Article
8. Kahan J, Sundararajan S, Brown K, Dinkin M, Oliveira C, Patsalides A. Predicting the need for retreatment in venous sinus stenting for idiopathic intracranial hypertension. J Neurointerv Surg. 2021; 13:574–579.
Article
9. Tan MG, Worley B, Kim WB, Ten Hove M, Beecker J. Drug-induced intracranial hypertension: a systematic review and critical assessment of drug-induced causes. Am J Clin Dermatol. 2020; 21:163–172.
Article
10. Taoka T, Naganawa S. Neurofluid dynamics and the glymphatic system: a neuroimaging perspective. Korean J Radiol. 2020; 21:1199–1209.
Article